Comparative Pharmacology
Head-to-head clinical analysis: DIETHYLPROPION HYDROCHLORIDE versus MERIDIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIETHYLPROPION HYDROCHLORIDE versus MERIDIA.
DIETHYLPROPION HYDROCHLORIDE vs MERIDIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sympathomimetic amine with anorectic activity; stimulates release of norepinephrine and dopamine from presynaptic nerve terminals in the hypothalamus, leading to appetite suppression.
Sibutramine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that inhibits the reuptake of serotonin and norepinephrine in the hypothalamus, enhancing satiety and increasing energy expenditure.
25 mg orally three times daily, 1 hour before meals; extended-release: 75 mg orally once daily in midmorning.
10–15 mg orally once daily, titrated to 15 mg maximum after 4 weeks if inadequate weight loss.
None Documented
None Documented
4-6 hours (parent drug); clinical effects correlate with plasma levels, requiring multiple daily dosing.
Sibutramine: 1.1 hours; active metabolites M1 and M2: 14-16 hours (terminal half-life). Steady-state achieved within 4 days.
Approximately 70-80% of the dose is excreted renally as metabolites; less than 10% as unchanged drug. Biliary/fecal excretion accounts for the remainder.
Primarily hepatic (CYP3A4 metabolism) with renal excretion of metabolites; ~80% of dose excreted in urine (mainly as M1 and M2 metabolites) and ~10% in feces.
Category C
Category C
Appetite Suppressant
Appetite Suppressant